As of May 18
| -0.05 / -1.67%|
The 3 analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 5.00, with a high estimate of 6.00 and a low estimate of 2.50. The median estimate represents a +69.49% increase from the last price of 2.95.
The current consensus among 3 polled investment analysts is to Buy stock in AcelRx Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.